Table 2: Unadjusted and Multivariable Adjusted Modeling for Parameters Associated with Renal Function, in the Studied Patient Population.

Parameters Values obtained when comparing Tenofovir-exposed with Tenofovir-unexposed1 subjects
Unadjusted P value Adjusted model2 P value
Change in GFR3 at 24 months:
- overall
- 50 < baseline GFR ≤ 80
- baseline GFR >80
-5.9 (-8.1 to -3.7)
-2.8 (-4.7 to -0.9)
-6.4 (-8.6 to -4.3)
<0.001
0.003
<0.001
-5.1 (-7.6 to -3.8)
-2.1 (-4.2 to -0.6)
-5.8 (-8.1 to -3.9)
<0.001
0.005
<0.001
GFR decreased >50% from baseline hazard ratio 1.62 (0.91 to 2.65) 0.065 1.45 (0.82 to 2.31) 0.078
Change in SCr4 +0.09 (+0.06 to +0.11) 0.021 +0.06 (+0.04 to +0.09) 0.035
Development proximal tubular dysfunction hazard ratio 6.12 (2.75 to 14.21) <0.001 5.78 (2.34 to 13.66) <0.001

1 Results are mean estimate (95% confidence interval).
2 Multivariate modeling by linear repeated measures for continuous outcomes and Cox proportional hazard modeling for dichotomous parameters. Predictor variables include age, gender, Black race, baseline creatinine, CD4 lymphocyte count, antiretroviral regimen, diabetes mellitus, arterial hypertension, malignancies, full-blown acquired immunodeficiency syndrome, chronic hepatitis B or C, current use of diuretics or angiotensin converting enzyme inhibitors. Final model developed by backward selection until all covariates were at P < 0.10 level.
3 Estimated glomerular filtration rate (GFR) calculated by MDRD formula, adjusted per body surface area (mL/min/1.73m2).
4 SCr, serum creatinine (mg/dL).